94
Participants
Start Date
December 14, 2023
Primary Completion Date
December 13, 2027
Study Completion Date
December 13, 2027
AZD5851
"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce AZD5851.~During AZD5851 production, subjects may receive bridging therapy for disease control. Upon successful generation of AZD5851 product, subjects will receive treatment with AZD5851 therapy.~Study treatment will include lymphodepleting chemotherapy followed by one dose of AZD5851 administered by intravenous (IV) infusion."
Research Site, New York
Research Site, Pittsburgh
Research Site, Philadelphia
Research Site, Washington D.C.
Research Site, Atlanta
Research Site, Jacksonville
Research Site, Columbus
Research Site, Rochester
Research Site, Westwood
Research Site, Phoenix
Research Site, Duarte
Research Site, Orange
Research Site, San Francisco
Research Site, Portland
Research Site, Hackensack
Research Site, Chūōku
Research Site, Kashiwa
Research Site, Kyoto
Research Site, Osakasayama-shi
Research Site, Seoul
Lead Sponsor
AstraZeneca
INDUSTRY